PHILLIP BOWMAN: Open Payments
NPI 1295702710 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$227,918 in 376 payments from 21 companies in 2025. Trend: 2023 $171,258 · 2024 $159,597 · 2025 $227,918
Speaker / faculty: $140,395Honoraria: $33,150Travel & lodging: $26,152Consulting: $18,510Food & beverage: $9,711
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 161 | $151,903 |
| Axsome Therapeutics, Inc. | 62 | $43,815 |
| Vanda Pharmaceuticals Inc. | 37 | $17,160 |
| Alkermes, Inc. | 20 | $12,397 |
| Neurocrine BioSciences, Inc. | 19 | $770 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $251 |
| Janssen Pharmaceuticals, Inc | 11 | $230 |
| Otsuka America Pharmaceutical, Inc. | 7 | $181 |
| Collegium Pharmaceutical, Inc. | 8 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $169 |
Products named: VRAYLAR, Auvelity, FANAPT, LYBALVI, INGREZZA, CAPLYTA, ARISTADA, Jornay PM.
Industry payments across CA — which companies pay providers there.
